Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study-Reference-Cited by-同舟云学术

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study

Published:2021-07-31 Issue: Volume: Page:
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Akizawa Tadao¹^ORCID,Nobori Kiyoshi²,Matsuda Yoshimi²,Taki Kentaro³,Hayashi Yasuhiro³,Hayasaki Takanori³,Yamamoto Hiroyasu⁴

Affiliation:

1. Division of Nephrology, Department of Medicine Showa University School of Medicine Tokyo Japan

2. Bayer Yakuhin Ltd, Research & Development Japan Osaka Japan

3. Bayer Yakuhin Ltd Medical Affairs and Pharmacovigilance Osaka Japan

4. Division of Nephrology and Hypertension, Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Nephrology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.13713

Reference26 articles.

1. Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease;Kidney Disease;Kidney Int Suppl,2012

2. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

3. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

4. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

5. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous detection of three hypoxia‐inducible factor stabilizers—molidustat, roxadustat, and vadadustat—in multiple keratinized matrices and its application in a doping context;Drug Testing and Analysis;2024-07-11

2. Scaffold hopping strategy to derive 4‐hydroxy‐1‐alkyl‐2‐oxo‐1,2‐dihydrothieno[2,3‐b:4,5‐b′]dipyridine‐3‐carbonylglycine derivatives as a novel hypoxia‐inducible factor prolyl hydroxylase domain inhibitor for the potential treatment of chronic kidney disease anemia;Bulletin of the Korean Chemical Society;2023-01-19

3. Management of Anemia in Peritoneal Dialysis Patients;Nolph and Gokal's Textbook of Peritoneal Dialysis;2023

4. Anemia and Disorders of Hemostasis in Chronic Kidney Disease;Management of Chronic Kidney Disease;2023

5. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors;Drugs;2022-11